Tela Bio Inc (TELA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tela Bio Inc (TELA) has a cash flow conversion efficiency ratio of -3.673x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.72 Million) by net assets ($1.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tela Bio Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Tela Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Tela Bio Inc for a breakdown of total debt and financial obligations.
Tela Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tela Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ENERSIDE ENERGY EO -01
F:9O8
|
N/A |
|
Daewon Co. Ltd
KQ:007680
|
0.059x |
|
Dancomech Holdings Bhd
KLSE:5276
|
0.030x |
|
Changchai Co Ltd
SHE:200570
|
-0.017x |
|
Chia Ta World Co Ltd
TW:2033
|
0.042x |
|
Prefab Bucures
RO:PREH
|
0.052x |
|
Rightmove PLC
LSE:RMV
|
1.426x |
|
Jubilee Enterprise Public Company Limited
BK:JUBILE
|
0.031x |
Annual Cash Flow Conversion Efficiency for Tela Bio Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Tela Bio Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see TELA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $28.46 Million | $-41.59 Million | -1.462x | +32.45% |
| 2023-12-31 | $18.88 Million | $-40.86 Million | -2.164x | +24.03% |
| 2022-12-31 | $14.30 Million | $-40.75 Million | -2.849x | -88.12% |
| 2021-12-31 | $20.10 Million | $-30.43 Million | -1.514x | -203.54% |
| 2020-12-31 | $49.03 Million | $-24.46 Million | -0.499x | +39.49% |
| 2019-12-31 | $30.96 Million | $-25.52 Million | -0.824x | -670.38% |
| 2018-12-31 | $-137.86 Million | $-19.92 Million | 0.145x | -4.49% |
| 2017-12-31 | $-108.17 Million | $-16.37 Million | 0.151x | -- |
About Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue… Read more